Drug recall · June 21, 2023
Lysteda recall
Why: Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Lysteda (tranexamic acid) USP Tablets, 650 mg, 30 tablets per bottle, Rx Only, Manufactured for: Amring Pharmaceuticals Inc. Berwyn, PA 19312, NDC 69918-301-30
- Lots / codes
Lots: X220317A and X220318A, exp. date 09/25
- Quantity
- 48,989 bottles
- Company
- Amring Pharmaceuticals Inc, Berwyn, PA
- Distribution
- Nationwide in the USA.
- Initiated
- June 12, 2023 · Voluntary: Firm initiated
- Classified
- June 14, 2023
- Reported
- June 21, 2023
- Ended
- May 29, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Tranexamic acid
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.